The impact of sex partners' HIV status on HIV seroconversion in a prospective cohort of injection drug users

Journal of Acquired Immune Deficiency Syndromes

Volumn 41, Issue 1, 2006, Pages 119-123

  Kerr, Thomas ^a,b,d   Stoltz, Jo Anne ^a   Strathdee, Steffanie ^c   Li, Kathy ^a   Hogg, Robert S ^a,b   Montaner, Julio S ^a,b   Wood, Evan ^a,b  

^a ST PAUL S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

Author keywords

HIV; HIV infection; HIV AIDS; Injection drug use; Sexual partners

Indexed keywords

ADULT; ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG USE; FEMALE; HEALTH HAZARD; HEALTH STATUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANK SUM TEST; SEROCONVERSION; SEXUALITY; STATISTICAL SIGNIFICANCE;

AIDS SERODIAGNOSIS; BRITISH COLUMBIA; COHORT STUDIES; ETHNIC GROUPS; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; PROSPECTIVE STUDIES; SEXUAL BEHAVIOR; SUBSTANCE ABUSE, INTRAVENOUS; TIME FACTORS;

EID: 28944443409     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000179429.57531.47     Document Type: Article

References (23)

1. American Society of Addiction Medicine. Public policy statement on national drug policy. J Addict Dis. 1994;13:231-234.
2. Wall R, Rehm J, Fischer B, et al. Social costs of untreated opioid dependence. J Urban Health. 2000;77:688-722.
3. Palepu A, Tyndall MW, Leon H, et al. Hospital utilization and costs in a cohort of injection drug users. Can Med Assoc J. 2001;165:415-420.
4. Wood E, Kerr T, Spittal PM, et al. The healthcare and fiscal costs of the illicit drug use epidemic: the impact of conventional drug control strategies and the impact of a comprehensive approach. British Columbia Medical Journal. 2003;45:130-136.
5. Miller CL, Johnston C, Spittal PM, et al. Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users. Hepatology. 2002;36:737-742.
6. Kitayaporn D, Uneklabh C, Weniger BG, et al. HIV-1 incidence determined retrospectively among drug users in Bangkok, Thailand [see comments]. AIDS. 1994;8:1443-1450.
7. Galai N, Safaeian M, Vlahov D, et al. Longitudinal patterns of drug injection behavior in the ALIVE Study cohort, 1988-2000: description and determinants. Am J Epidemiol. 2003;158:695-704.
8. Schoenbaum EE, Hartel D, Selwyn PA, et al. Risk factors for human immunodeficiency virus infection in intravenous drug users. N Engl J Med. 1989;321:874-879.
9. Titti F, Rezza G, Verani P, et al. HIV, HTLV-1, and HBV infections in a cohort of Italian intravenous drug abusers: analysis of risk factors. J Acquir Immune Defic Syndr Hum Retrovirol. 1988;1:405-411.
10. Des Jarlais DC, Friedman SR. HIV epidemiology and interventions among injecting drug users. Int J STD AIDS. 1996;7:57-61.
11. Williams ML, Bowen AM, Timpson S, et al. Drug injection and sexual mixing patterns of drug-using male sex workers. Sex Transm Dis. 2003;30:571-574.
12. Wood E, Tyndall MW, Spittal PM, et al. Unsafe injection practices in a cohort of injection drug users in Vancouver: could safer injecting rooms help? Can Med Assoc J. 2001;165:405-410.
13. Tyndall MW, Currie S, Spittal P, et al. Intensive injection cocaine use as the primary risk factor in the Vancouver HIV-1 epidemic. AIDS. 2003;17:887-893.
14. Spittal PM, Craib KJ, Wood E, et al. Risk factors for elevated HIV incidence rates among female injection drug users in Vancouver. Can Med Assoc J. 2002;166:894-899.
15. Craib KJ, Spittal PM, Wood E, et al. Risk factors for elevated HIV incidence among Aboriginal injection drug users in Vancouver. Can Med Assoc J. 2003;168:19-24.
16. Tyndall MW, Spittal PM, Laliberte N, et al. Intensive injection cocaine use as a primary risk factor of HIV seroconversion among polydrug users in Vancouver. AIDS. 2002;17:887-893.
17. Strathdee SA, Patrick DM, Currie SL, et al. Needle exchange is not enough: lessons from the Vancouver Injecting Drug Use Study. AIDS. 1997;11(Suppl):F59-F65.
18. Miller CL, Spittal PM, LaLiberte N, et al. Females experiencing sexual and drug vulnerabilities are at elevated risk for HIV infection among youth who use injection drugs. J Acquir Immune Defic Syndr. 2002;30:335-341.
19. Des Jarlais DC, Padian NS, Winkelstein W Jr. Targeted HIV-prevention programs. N Engl J Med. 1994;331:1451-1453.
20. Des Jarlais DC, Paone D, Milliken J, et al. Audio-computer interviewing to measure risk behaviour for HIV among injecting drug users: a quasi-randomised trial. Lancet. 1999;353:1657-1661.
21. Janssen RS, Holtgrave DR, Valdiserri RO, et al. The serostatus approach to fighting the HIV epidemic: prevention strategies for infected individuals. Am J Public Health. 2001;91:1019-1024.
22. Golden MR, Brewer DD, Kurth A, et al. Importance of sex partner HIV status in HIV risk assessment among men who have sex with men. J Acquir Immune Defic Syndr. 2004;36:734-742.
23. Wood E, Schlechter MT, Tyndall MW, et al. Antiretroviral medication use among injection drug users: two potential futures. AIDS. 2000;14:1229-1235.